https://www.yiliao.com/index.php?action=history&feed=atom&title=FS-1502
FS-1502 - 版本历史
2026-04-18T23:04:31Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=FS-1502&diff=314600&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T02:39:28Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[FS-1502]]</strong>（商品名：<strong>[[云欣替康]]</strong>）是一种创新的针对<strong>[[HER2]]</strong>（[[人表皮生长因子受体2]]）靶点的<strong>[[抗体偶联药物]]</strong>（[[ADC]]）。该药物由<strong>[[复创医药]]</strong>（[[Fochon Pharma]]，[[复星医药]]子公司）自主研发，由人源化[[HER2]]单克隆抗体通过可裂解连接子与高效的<strong>[[拓扑酶I抑制剂]]</strong>（[[Topoisomerase I inhibitor]]）毒素载荷偶联而成。[[FS-1502]]通过精准识别肿瘤细胞表面的[[HER2]]蛋白，通过[[内吞作用]]进入细胞并释放毒素，旨在解决<strong>[[HER2阳性]]</strong>及<strong>[[HER2低表达]]</strong>（[[HER2-low]]）实体瘤的临床需求，尤其是在[[乳腺癌]]和[[胃癌]]领域展现了极具竞争力的临床潜力。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[FS-1502]]</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">HER2-targeted ADC · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[ADC]]药物结构示意图</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">研发公司：复创医药 (Fochon)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">核心靶点</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[HER2]] / [[ERBB2]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">毒素载荷</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[拓扑酶I抑制剂]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[DAR]]值</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">平均约7-8</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[抗体偶联药物]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药途径</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[静脉滴注]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">研究状态</th><br />
<td style="padding: 12px; color: #0f172a;">临床II/III期</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：精准导向的细胞内生化打击</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[FS-1502]]采用新一代[[ADC]]技术架构，其抗肿瘤机制涵盖了直接靶向杀伤及特有的空间效应：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>精准受体结合：</strong>其人源化抗体部分以极高的亲和力结合肿瘤表面的[[HER2]]受体，确保了药物的特异性。</li><br />
<li style="margin-bottom: 12px;"><strong>高效内吞与降解：</strong>结合后形成的[[复合物]]通过受体介导的[[胞吞作用]]进入细胞。在[[溶酶体]]酸性环境或蛋白酶作用下，可裂解[[连接子]]（Linker）被切断。</li><br />
<li style="margin-bottom: 12px;"><strong>DNA损伤诱导：</strong>释放出的活性载荷（[[拓扑酶I抑制剂]]）进入细胞核，抑制[[DNA]]复制过程，引发[[双链断裂]]，最终诱导细胞凋亡。</li><br />
<li style="margin-bottom: 12px;"><strong>[[旁路杀伤效应]]（Bystander Effect）：</strong>[[FS-1502]]携带的毒素具有良好的[[膜通透性]]，能够穿过细胞膜进入邻近的[[HER2]]阴性肿瘤细胞，有效克服肿瘤的[[异质性]]。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：FS-1502应用研究矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病领域</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">研究阶段</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">核心临床表现</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2阳性乳腺癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">注册临床/III期</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">在多线治疗进展后的患者中显示出显著的[[ORR]]（客观缓解率）。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2低表达乳腺癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">临床II期探索</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">利用[[旁路杀伤]]，在[[IHC]] 1+或2+/[[FISH]]阴性人群中表现活跃。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[晚期胃癌]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">临床II期</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">针对[[赫赛汀]]耐药后的二线及后线治疗，展示了深度缓解。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从耐药管理到跨靶点协同</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[FS-1502]]的开发策略旨在打破传统抗[[HER2]]药物的局限：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>高载荷平衡：</strong>通过优化的[[DAR]]值（药物抗体比），在确保抗肿瘤强度的同时，最大程度减少因循环中载荷脱落引起的[[间质性肺炎]]（[[ILD]]）或[[中性粒细胞减少]]。</li><br />
<li style="margin-bottom: 12px;"><strong>耐药后的精准替代：</strong>针对接受过[[曲妥珠单抗]]、[[拉帕替尼]]治疗失败的患者，[[FS-1502]]作为一种作用机制截然不同的“[[特洛伊木马]]”，提供了新的挽救机会。</li><br />
<li style="margin-bottom: 12px;"><strong>安全性分层：</strong>在临床实践中，需密切监测[[血液学毒性]]及肝功能指标，特别是针对联合[[化疗]]或[[免疫治疗]]的探索性方案。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[HER2]]：</strong>细胞表面受体，其过表达是多种恶性肿瘤的驱动因素。</li><br />
<li style="margin-bottom: 8px;"><strong>[[DS-8201]] (Enhertu)：</strong>全球[[HER2-ADC]]的标杆药物，[[FS-1502]]常与其进行疗效及安全性对标。</li><br />
<li style="margin-bottom: 8px;"><strong>[[旁路杀伤]]：</strong>[[ADC]]毒素弥散至相邻细胞的特性，是解决肿瘤异质性的关键。</li><br />
<li style="margin-bottom: 8px;"><strong>[[拓扑酶I抑制剂]]：</strong>一类抑制[[DNA]]螺旋解链的毒素，是新一代[[ADC]]的主流载荷。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Wu J, et al. (2022).</strong> <em>Phase Ia/Ib study of FS-1502, a HER2-targeted ADC, in patients with HER2-positive metastatic breast cancer.</em> <strong>[[Journal of Clinical Oncology]]</strong> (ASCO Abstract).[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：早期数据确立了FS-1502在多线经治 breast cancer 患者中的耐受性与初步疗效。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Fochon Pharmaceutical Research Team. (2024 update).</strong> <em>Structural logic and payload optimization of FS-1502 against HER2-low tumors.</em> <strong>[[Cancer Cell International]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：深度解析了中国本土ADC药物在分子设计上的差异化优势，尤其是其针对低表达人群的响应率。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[FS-1502]] ([[云欣替康]]) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联品种</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Enhertu]]•[[Kadcyla]]•[[RC48]]•[[A166]]•[[SHR-A1811]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[复星医药]]•[[Fochon Pharma]]•[[NMPA]]•[[复宏汉霖]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心适应症</td><br />
<td style="padding: 10px 15px; color: #334155;">[[转移性乳腺癌]]•[[HER2阳性胃癌]]•[[非小细胞肺癌]]•[[结直肠癌]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿方向</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ADC与PD-1联合治疗]]•[[针对脑转移的入脑性探索]]•[[早期辅助治疗应用]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164